lamotrigine has been researched along with Delayed Effects, Prenatal Exposure in 50 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To provide an overview of the available literature concerning the prevention of congenital malformations following the use of lamotrigine (LMT) during pregnancy." | 8.85 | [Teratogenic effects of lamotrigine in women with bipolar disorder]. ( Berwaerts, K; De Fruyt, J; Sienaert, P, 2009) |
| "Callers who contacted the Israeli Teratology Information Service regarding lamotrigine treatment or NTE during pregnancy between 1997 and 2008 were prospectively followed-up." | 7.85 | Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. ( Diav-Citrin, O; Finkel-Pekarsky, V; Ornoy, A; Shechtman, S; Zvi, N, 2017) |
| "The infant exposed in the first trimester of pregnancy to the anticonvulsant drug lamotrigine has an increased risk to have an isolated cleft palate or cleft lip deformity." | 7.74 | Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. ( Baldwin, EJ; Glassman, L; Habecker, E; Holmes, LB; Smith, CR; Wong, SL; Wyszynski, DF, 2008) |
| "To report the frequency of major malformations in lamotrigine-exposed pregnancies from September 1, 1992, through March 31, 2004, in the International Lamotrigine Pregnancy Registry." | 7.73 | Lamotrigine and the risk of malformations in pregnancy. ( Cunnington, M; Tennis, P, 2005) |
| " The mother had been treated with valproic acid (1800mg per day) and lamotrigine (100mg per day) throughout pregnancy." | 7.72 | Valproic acid and lamotrigine treatment during pregnancy. The risk of chromosomal abnormality. ( Cogulu, O; Gunduz, C; Kultursay, N; Ozkinay, F; Yilmaz, D, 2003) |
| "Pregnancy is a state where drug pharmacokinetic changes are more pronounced and more rapid than any other period of life." | 5.48 | Effect of zonisamide on refractory epilepsy during pregnancy in lamotrigine resistant kindled rats. ( Keramati, K; Mahdavi, A; Moezifar, M; Narenji Sani, R; Saberi, N, 2018) |
| "In this prospective, observational, assessor-masked, multicentre study, we enrolled pregnant women with epilepsy on antiepileptic drug monotherapy (carbamazepine, lamotrigine, phenytoin, or valproate) between October, 1999, and February, 2004, at 25 epilepsy centres in the UK and the USA." | 5.17 | Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. ( Baker, GA; Bromley, RL; Browning, N; Clayton-Smith, J; Cohen, MJ; Kalayjian, LA; Kanner, A; Liporace, JD; Loring, DW; Meador, KJ; Pennell, PB; Privitera, M, 2013) |
| " Oxcarbazepine and lamotrigine were associated with increased occurrence of autism." | 4.95 | Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. ( Cogo, E; D'Souza, J; Finkelstein, Y; Hemmelgarn, BR; Hutton, B; Kealey, R; MacDonald, H; Reynen, E; Rios, P; Soobiah, C; Straus, SE; Thavorn, K; Tricco, AC; Veroniki, AA; Yazdi, F, 2017) |
| "To provide an overview of the available literature concerning the prevention of congenital malformations following the use of lamotrigine (LMT) during pregnancy." | 4.85 | [Teratogenic effects of lamotrigine in women with bipolar disorder]. ( Berwaerts, K; De Fruyt, J; Sienaert, P, 2009) |
| "To investigate whether children born to mothers who used carbamazepine during pregnancy had worse academic performance in adolescence." | 4.31 | Prenatal Carbamazepine Exposure and Academic Performance in Adolescents: A Population-Based Cohort Study. ( Lee, PMY; Li, F; Li, J; Ren, T, 2023) |
| "Findings from this explorative study strengthen the evidence for the warning against the use of valproate in pregnancy and raise concern of risks of specific psychiatric disorders associated with topiramate and levetiracetam." | 4.31 | Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders. ( Alvestad, S; Bjørk, MH; Christensen, J; Cohen, JM; Dreier, JW; Furu, K; Gissler, M; Igland, J; Leinonen, MK; Sun, Y; Tomson, T; Zoega, H, 2023) |
| "Despite widespread monotherapy use of lamotrigine or levetiracetam during pregnancy, prospectively collected, blinded child development data are still limited." | 4.31 | Neurodevelopment of babies born to mothers with epilepsy: A prospective observational cohort study. ( Bromley, RL; Bullen, P; Campbell, E; Clayton-Smith, J; Craig, J; García-Fiñana, M; Hughes, DM; Ingham, A; Irwin, B; Jackson, C; Kelly, T; Morrow, J; Rushton, S; Winterbottom, J; Wood, A; Yates, LM, 2023) |
| "The study included the children of 83 epileptic women treated with lamotrigine during pregnancy, at a tertiary medical centre between 2004-2014." | 3.88 | Short- and long-term complications of in utero exposure to lamotrigine. ( Berger, I; Cohen-Israel, M; Klinger, G; Linder, N; Martonovich, EY; Stahl, B, 2018) |
| "Callers who contacted the Israeli Teratology Information Service regarding lamotrigine treatment or NTE during pregnancy between 1997 and 2008 were prospectively followed-up." | 3.85 | Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. ( Diav-Citrin, O; Finkel-Pekarsky, V; Ornoy, A; Shechtman, S; Zvi, N, 2017) |
| "To determine the frequency of malformations among infants born to women who had taken lamotrigine or carbamazepine as part of polytherapy during the first trimester of pregnancy." | 3.77 | Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. ( Hernandez-Diaz, S; Holmes, LB; Mittendorf, R; Shen, A; Smith, CR, 2011) |
| " Between 1999 and 2004, we enrolled pregnant women with epilepsy who were taking a single AED (carbamazepine, lamotrigine, phenytoin, or valproate)." | 3.76 | Effects of breastfeeding in children of women taking antiepileptic drugs. ( Baker, GA; Browning, N; Clayton-Smith, J; Cohen, M; Combs-Cantrell, DT; Kalayjian, LA; Kanner, A; Liporace, JD; Loring, DW; Meador, KJ; Pennell, PB; Privitera, M, 2010) |
| "Between 1999 and 2004, we enrolled pregnant women with epilepsy who were taking a single antiepileptic agent (carbamazepine, lamotrigine, phenytoin, or valproate) in a prospective, observational, multicenter study in the United States and the United Kingdom." | 3.75 | Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. ( Baker, GA; Browning, N; Clayton-Smith, J; Cohen, M; Combs-Cantrell, DT; Kalayjian, LA; Kanner, A; Liporace, JD; Loring, DW; Meador, KJ; Pennell, PB; Privitera, M, 2009) |
| "This substudy of the Neurodevelopmental Effects of Antiepileptic Drugs investigation enrolled pregnant women with epilepsy on AED monotherapy (carbamazepine, lamotrigine, and valproate)." | 3.75 | A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. ( Gaillard, WD; McVearry, KM; Meador, KJ; VanMeter, J, 2009) |
| "(1) Numerous follow-up studies of pregnancies in women with epilepsy show that valproic acid is more teratogenic than other antiepileptics." | 3.75 | Valproic acid: long-term effects on children exposed in utero. ( , 2009) |
| "The infant exposed in the first trimester of pregnancy to the anticonvulsant drug lamotrigine has an increased risk to have an isolated cleft palate or cleft lip deformity." | 3.74 | Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. ( Baldwin, EJ; Glassman, L; Habecker, E; Holmes, LB; Smith, CR; Wong, SL; Wyszynski, DF, 2008) |
| "To report the frequency of major malformations in lamotrigine-exposed pregnancies from September 1, 1992, through March 31, 2004, in the International Lamotrigine Pregnancy Registry." | 3.73 | Lamotrigine and the risk of malformations in pregnancy. ( Cunnington, M; Tennis, P, 2005) |
| " The mother had been treated with valproic acid (1800mg per day) and lamotrigine (100mg per day) throughout pregnancy." | 3.72 | Valproic acid and lamotrigine treatment during pregnancy. The risk of chromosomal abnormality. ( Cogulu, O; Gunduz, C; Kultursay, N; Ozkinay, F; Yilmaz, D, 2003) |
| "Epilepsy affects fetal brain development during gestation in pregnant rats, therefore anti-epileptic therapy should be continued during pregnancy." | 2.53 | Effects of phenytoin and lamotrigine treatment on serum BDNF levels in offsprings of epileptic rats. ( Doğan, Z; Kamışlı, Ö; Soysal, H, 2016) |
| "Planned pregnancy was the only independent factor significantly associated with decreased risk of adverse pregnancy outcomes (OR, 0." | 1.72 | Effects of antiepileptic drugs polytherapy on pregnancy outcomes in women with epilepsy: An observation study in northwest China. ( Jiang, W; Jiang, Y; Ma, L; Shi, X; Song, C; Wang, Y; Xia, L; Zhang, Y; Zhao, J, 2022) |
| "To study the risk of intellectual disability and delayed development in childhood milestones among children of women who used valproate or other AEDs during pregnancy." | 1.56 | Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Intellectual Disability and Delayed Childhood Milestones. ( Christensen, J; Daugaard, CA; Dreier, JW; Pedersen, L; Sun, Y, 2020) |
| "Pregnancy is a state where drug pharmacokinetic changes are more pronounced and more rapid than any other period of life." | 1.48 | Effect of zonisamide on refractory epilepsy during pregnancy in lamotrigine resistant kindled rats. ( Keramati, K; Mahdavi, A; Moezifar, M; Narenji Sani, R; Saberi, N, 2018) |
| "We believe that the neonatal seizures were caused by lamotrigin withdrawal." | 1.35 | [Neonatal seizures caused by lamotrigin withdrawal?]. ( Längler, A; Thiel, M; Vieker, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (30.00) | 29.6817 |
| 2010's | 23 (46.00) | 24.3611 |
| 2020's | 12 (24.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bjørk, MH | 2 |
| Zoega, H | 2 |
| Leinonen, MK | 2 |
| Cohen, JM | 2 |
| Dreier, JW | 3 |
| Furu, K | 2 |
| Gilhus, NE | 1 |
| Gissler, M | 2 |
| Hálfdánarson, Ó | 1 |
| Igland, J | 2 |
| Sun, Y | 3 |
| Tomson, T | 5 |
| Alvestad, S | 2 |
| Christensen, J | 4 |
| Shi, X | 1 |
| Wang, Y | 1 |
| Zhang, Y | 1 |
| Song, C | 1 |
| Jiang, Y | 1 |
| Zhao, J | 1 |
| Xia, L | 1 |
| Ma, L | 1 |
| Jiang, W | 1 |
| Ren, T | 1 |
| Lee, PMY | 1 |
| Li, F | 1 |
| Li, J | 1 |
| Bromley, RL | 5 |
| Bullen, P | 1 |
| Campbell, E | 1 |
| Craig, J | 2 |
| Ingham, A | 1 |
| Irwin, B | 1 |
| Jackson, C | 1 |
| Kelly, T | 1 |
| Morrow, J | 2 |
| Rushton, S | 1 |
| García-Fiñana, M | 3 |
| Hughes, DM | 1 |
| Winterbottom, J | 1 |
| Wood, A | 1 |
| Yates, LM | 1 |
| Clayton-Smith, J | 8 |
| Bromley, R | 1 |
| Adab, N | 1 |
| Bluett-Duncan, M | 1 |
| Edwards, K | 1 |
| Greenhalgh, J | 1 |
| Hill, RA | 1 |
| Jackson, CF | 1 |
| Khanom, S | 1 |
| McGinty, RN | 1 |
| Tudur Smith, C | 1 |
| Pulman, J | 1 |
| Marson, AG | 1 |
| Angus-Leppan, H | 1 |
| Moghim, MM | 1 |
| Cock, H | 1 |
| Kinton, L | 1 |
| Synnott Wells, M | 1 |
| Shankar, R | 1 |
| Huber-Mollema, Y | 2 |
| van Iterson, L | 1 |
| Oort, FJ | 2 |
| Lindhout, D | 3 |
| Rodenburg, R | 2 |
| Clark, CT | 1 |
| Wiggs, KK | 1 |
| Rickert, ME | 1 |
| Sujan, AC | 1 |
| Quinn, PD | 1 |
| Larsson, H | 1 |
| Lichtenstein, P | 1 |
| Oberg, AS | 1 |
| D'Onofrio, BM | 1 |
| Daugaard, CA | 1 |
| Pedersen, L | 1 |
| Kakumoto, M | 1 |
| Shimokawa, K | 1 |
| Ueshima, S | 1 |
| Hira, D | 1 |
| Okano, T | 1 |
| Diav-Citrin, O | 1 |
| Shechtman, S | 1 |
| Zvi, N | 1 |
| Finkel-Pekarsky, V | 1 |
| Ornoy, A | 2 |
| Veroniki, AA | 1 |
| Rios, P | 1 |
| Cogo, E | 1 |
| Straus, SE | 1 |
| Finkelstein, Y | 1 |
| Kealey, R | 1 |
| Reynen, E | 1 |
| Soobiah, C | 1 |
| Thavorn, K | 1 |
| Hutton, B | 1 |
| Hemmelgarn, BR | 1 |
| Yazdi, F | 1 |
| D'Souza, J | 1 |
| MacDonald, H | 1 |
| Tricco, AC | 1 |
| Cohen-Israel, M | 1 |
| Berger, I | 1 |
| Martonovich, EY | 1 |
| Klinger, G | 1 |
| Stahl, B | 1 |
| Linder, N | 1 |
| Narenji Sani, R | 1 |
| Keramati, K | 1 |
| Saberi, N | 1 |
| Moezifar, M | 1 |
| Mahdavi, A | 1 |
| Galappatthy, P | 1 |
| Liyanage, CK | 1 |
| Lucas, MN | 1 |
| Jayasekara, DTLM | 1 |
| Abhayaratna, SA | 1 |
| Weeraratne, C | 1 |
| De Abrew, K | 1 |
| Gunaratne, PS | 1 |
| Gamage, R | 1 |
| Wijeyaratne, CN | 1 |
| Cohen, MJ | 3 |
| Meador, KJ | 6 |
| May, R | 1 |
| Loblein, H | 1 |
| Conrad, T | 1 |
| Baker, GA | 6 |
| Kalayjian, LA | 5 |
| Kanner, A | 4 |
| Liporace, JD | 4 |
| Pennell, PB | 4 |
| Privitera, M | 4 |
| Loring, DW | 5 |
| Richards, N | 1 |
| Reith, D | 1 |
| Stitely, M | 1 |
| Smith, A | 1 |
| Rihtman, T | 1 |
| Parush, S | 1 |
| Verrotti, A | 1 |
| Scaparrotta, A | 1 |
| Cofini, M | 1 |
| Chiarelli, F | 1 |
| Tiboni, GM | 1 |
| Briggs, M | 2 |
| Cheyne, CP | 1 |
| Gummery, A | 1 |
| Kneen, R | 2 |
| Mawer, G | 1 |
| Shallcross, R | 2 |
| Klein, P | 1 |
| Janszky, J | 1 |
| Soysal, H | 1 |
| Doğan, Z | 1 |
| Kamışlı, Ö | 1 |
| Dolk, H | 1 |
| Jentink, J | 1 |
| Loane, M | 1 |
| Morris, J | 1 |
| de Jong-van den Berg, LT | 1 |
| Hunt, SJ | 1 |
| Craig, JJ | 1 |
| Morrow, JI | 1 |
| Vieker, S | 1 |
| Thiel, M | 1 |
| Längler, A | 1 |
| Browning, N | 3 |
| Combs-Cantrell, DT | 2 |
| Cohen, M | 2 |
| Berwaerts, K | 1 |
| Sienaert, P | 1 |
| De Fruyt, J | 1 |
| McVearry, KM | 1 |
| Gaillard, WD | 1 |
| VanMeter, J | 1 |
| Forcelli, PA | 1 |
| Janssen, MJ | 1 |
| Stamps, LA | 1 |
| Sweeney, C | 1 |
| Vicini, S | 1 |
| Gale, K | 1 |
| Madadi, P | 1 |
| Ito, S | 1 |
| Cummings, C | 1 |
| Stewart, M | 1 |
| Stevenson, M | 1 |
| Nelson, J | 1 |
| Battino, D | 1 |
| Bonizzoni, E | 1 |
| Sabers, A | 1 |
| Perucca, E | 1 |
| Vajda, F | 1 |
| Holmes, LB | 2 |
| Mittendorf, R | 1 |
| Shen, A | 1 |
| Smith, CR | 2 |
| Hernandez-Diaz, S | 1 |
| Mawer, GE | 1 |
| Cheyne, C | 1 |
| Lucas, SB | 1 |
| Smyth, MD | 1 |
| Barbaro, NM | 1 |
| Baraban, SC | 1 |
| Kalkman, HO | 1 |
| Ozkinay, F | 1 |
| Cogulu, O | 1 |
| Gunduz, C | 1 |
| Yilmaz, D | 1 |
| Kultursay, N | 1 |
| Yonkers, KA | 1 |
| Wisner, KL | 1 |
| Stowe, Z | 1 |
| Leibenluft, E | 1 |
| Cohen, L | 1 |
| Miller, L | 1 |
| Manber, R | 1 |
| Viguera, A | 1 |
| Suppes, T | 1 |
| Altshuler, L | 1 |
| Penovich, P | 1 |
| Gaily, E | 1 |
| Cunnington, M | 1 |
| Tennis, P | 1 |
| Hauser, WA | 1 |
| Baldwin, EJ | 1 |
| Habecker, E | 1 |
| Glassman, L | 1 |
| Wong, SL | 1 |
| Wyszynski, DF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Neurodevelopmental Effects of Antiepileptic Drugs II: the NEAD Study[NCT00021866] | 331 participants (Actual) | Observational | 2000-09-30 | Completed | |||
| Lamotrigine Pregnancy Registry (LAM05)[NCT01064297] | 3,416 participants (Actual) | Observational | 2001-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of infants with major congenital malformations were counted and are presented by earliest trimester of exposure to lamotrigine polytherapy with valproate. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 14 |
| First Exposure During Second Trimester | 1 |
| First Exposure During Third Trimester | 0 |
| Unspecified Trimester of Exposure | 0 |
| All Trimesters | 1 |
The number of infants with major congenital malformations were counted and are presented by earliest trimester of exposure to lamotrigine polytherapy without valproate. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 12 |
| First Exposure During Second Trimester | 0 |
| First Exposure During Third Trimester | 1 |
| All Trimesters | 13 |
Among lamotrigine monotherapy exposures: live births, fetal deaths, induced abortions with birth defects, and live births without defects. Due to the likelihood of inconsistent identification of birth defects among spontaneous losses, fetal deaths, and induced abortions without reported birth defects, these offspring were not included in analyses. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 35 |
| First Exposure During Second Trimester | 4 |
| First Exposure During Third Trimester | 1 |
| Unspecified Trimester of Exposure | 0 |
| All Trimesters | 40 |
The number of live births, fetal deaths, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine monotherapy. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. (NCT01064297)
Timeframe: Although reports and diagnoses of major congenital malformations are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 31 | 1 | 3 | 1523 | 10 | 33 | 98 |
| First Exposure During Second Trimester | 4 | 0 | 0 | 91 | 0 | 0 | 0 |
| First Exposure During Third Trimester | 1 | 0 | 0 | 17 | 0 | 0 | 0 |
| Unspecified Trimester of Exposure | 0 | 0 | 0 | 5 | 0 | 0 | 0 |
The number of live births, fetal deaths, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine polytherapy with valproate. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 14 | 0 | 2 | 134 | 1 | 4 | 6 |
| First Exposure During Second Trimester | 1 | 0 | 0 | 6 | 1 | 0 | 0 |
| First Exposure During Third Trimester | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Unspecified Trimester of Exposure | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
The number of live births, fetal deaths with pregnancy loss occurring >=20 weeks gestation, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine polytherapy without valproate. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. Although birth defects may not have been reported, they cannot be ruled out. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 11 | 0 | 1 | 418 | 3 | 19 | 22 |
| First Exposure During Second Trimester | 0 | 0 | 0 | 25 | 0 | 0 | 0 |
| First Exposure During Third Trimester | 1 | 0 | 0 | 2 | 0 | 0 | 0 |
The number of infants with the reported MCM following first trimester exposure to lamotrigine polytherapy with valproate were counted. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hydrocephalus/spina bifida | Meningomyelocele | Microcephaly | Orofacial clefts | Cardiac septal defects | Transposition of great vessels | Ventricular hypoplasia | Pulmonary stenosis | Pyloric stenosis | Gastroschisis | Club foot | Polydactyly | |
| Doses Lower Than Prescribed | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Prescribed Doses | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The number of infants with the reported MCM following first trimester exposure to lamotrigine polytherapy without valproate were counted. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Neural tube defect | Cardiac septal defect/murmur | Coarctation of aorta | Tetralogy of Fallot | Esophageal defects | Hypospadias | Hydroencephalopathy | Omphalocele | Extra digit | Skin tags on ear | |
| Doses Higher Than Prescribed | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
| Doses Lower Than Prescribed | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Prescribed Doses | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
The number of infants with the reported MCM following first trimester lamotrigine monotherapy exposure were counted. Registry personnel contacted the enrolling physician to obtain information on the pregnancy outcome, lamotrigine dosing and duration of exposure, and use of concomitant antiepileptic drugs during pregnancy. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anencephaly | Orofacial clefts | Hypoplastic left heart/left ventricle hypoplasia | Transposition of great vessels | Ventricular septal defects | Minor heart defect, unspecified | Pulmonary stenosis | Hydronephrosis | Renal defect (absent, polysystic, fluid on kidney) | Cortical dysplasis | Hypospadias | Pyloric stenosis | Diaphragmatic hernia | Congenital atresia of anus | Hip dislocation | Club feet | Polydactyly | Epidermolysis bullosa | Light spot across entire abdomen | |
| Dose Higher Than Prescribed | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Doses Lower Than Prescribed | 2 | 2 | 1 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 |
| Prescribed Doses | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| Unknown Maximal Dose in Exposed Trimester | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
8 reviews available for lamotrigine and Delayed Effects, Prenatal Exposure
| Article | Year |
|---|---|
Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.
Topics: Child; Cohort Studies; Epilepsy; Female; Humans; Lamotrigine; Male; Phenytoin; Pregnancy; Prenatal E | 2023 |
Psychotropic drug use in perinatal women with bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Drug Elimination Routes; Fe | 2020 |
Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis.
Topics: Anticonvulsants; Autistic Disorder; Bayes Theorem; Breast Feeding; Carbamazepine; Child; Epilepsy; F | 2017 |
Developmental neurotoxicity and anticonvulsant drugs: a possible link.
Topics: Animals; Anticonvulsants; Breast Feeding; Carbamazepine; Cognition Disorders; Developmental Disabili | 2014 |
Effects of phenytoin and lamotrigine treatment on serum BDNF levels in offsprings of epileptic rats.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Disease Models, Animal; Electroencephal | 2016 |
[Teratogenic effects of lamotrigine in women with bipolar disorder].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Epilepsy; Fema | 2009 |
Antischizophrenic activity independent of dopamine D2 blockade.
Topics: Amino Acid Transport System X-AG; Animals; Antipsychotic Agents; Brain Chemistry; Dopamine D2 Recept | 2002 |
Management of bipolar disorder during pregnancy and the postpartum period.
Topics: Adolescent; Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbam | 2004 |
1 trial available for lamotrigine and Delayed Effects, Prenatal Exposure
| Article | Year |
|---|---|
Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study.
Topics: Adult; Anticonvulsants; Child; Child Development; Child, Preschool; Cognition; Epilepsy; Female; Hum | 2013 |
41 other studies available for lamotrigine and Delayed Effects, Prenatal Exposure
| Article | Year |
|---|---|
Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability.
Topics: Anticonvulsants; Autism Spectrum Disorder; Autistic Disorder; Carbamazepine; Child; Cohort Studies; | 2022 |
Effects of antiepileptic drugs polytherapy on pregnancy outcomes in women with epilepsy: An observation study in northwest China.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Male; Phenobarbital; Pregnanc | 2022 |
Prenatal Carbamazepine Exposure and Academic Performance in Adolescents: A Population-Based Cohort Study.
Topics: Academic Performance; Adolescent; Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Cohort Stu | 2023 |
Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders.
Topics: Adolescent; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Carbamazepine; Child; Ch | 2023 |
Neurodevelopment of babies born to mothers with epilepsy: A prospective observational cohort study.
Topics: Anticonvulsants; Child Development; Epilepsy; Female; Humans; Infant; Lamotrigine; Levetiracetam; Mo | 2023 |
Valproate risk form-Surveying 215 clinicians involving 4775 encounters.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Physicians | 2020 |
Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure.
Topics: Anticonvulsants; Carbamazepine; Child; Child Development; Cognitive Dysfunction; Female; Humans; Lam | 2020 |
Antiseizure medication use during pregnancy and risk of ASD and ADHD in children.
Topics: Adolescent; Adult; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Autism Spectrum D | 2020 |
Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Intellectual Disability and Delayed Childhood Milestones.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Clonazepam; Denmark; Developmen | 2020 |
Effects of antiepileptic drugs' administration during pregnancy on the nerve cell proliferation and axonal outgrowth of human neuroblastoma SH-SY5Y nerve cells.
Topics: Anticonvulsants; Carbamazepine; Cell Line, Tumor; Cell Proliferation; Child; Epilepsy; Female; Human | 2021 |
Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Congenital Abnormalities; Female; Humans; Lamotrigine; | 2017 |
Short- and long-term complications of in utero exposure to lamotrigine.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Child; Epilepsy; Female; Follow-Up Studies; Hum | 2018 |
Effect of zonisamide on refractory epilepsy during pregnancy in lamotrigine resistant kindled rats.
Topics: Animals; Animals, Newborn; Anticonvulsants; Brain; Drug Resistance; Drug Resistant Epilepsy; Female; | 2018 |
Obstetric outcomes and effects on babies born to women treated for epilepsy during pregnancy in a resource limited setting: a comparative cohort study.
Topics: Abortion, Spontaneous; Adolescent; Adult; Anticonvulsants; Body Height; Body Weight; Carbamazepine; | 2018 |
Fetal antiepileptic drug exposure and learning and memory functioning at 6 years of age: The NEAD prospective observational study.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Epilepsy; Female; Humans; Lamotrigine; Learning; Memor | 2019 |
Developmental outcomes at age four following maternal antiepileptic drug use.
Topics: Adult; Anticonvulsants; Carbamazepine; Child Development; Child, Preschool; Cohort Studies; Epilepsy | 2019 |
Behavioral problems in children of mothers with epilepsy prenatally exposed to valproate, carbamazepine, lamotrigine, or levetiracetam monotherapy.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Child Behavior Disorders; Epilepsy; Female; Humans; La | 2019 |
Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: cognitive, motor, sensory and behavioral function.
Topics: Anticonvulsants; Attention; Behavior; Child; Child, Preschool; Cognition; Faculty; Female; Humans; L | 2013 |
IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Child Development; Epilepsy; Female; Humans; Intellige | 2015 |
Fine-tuning risk assessment with antiepileptic drug use in pregnancy.
Topics: Anticonvulsants; Carbamazepine; Child Development; Epilepsy; Female; Humans; Intelligence; Lamotrigi | 2015 |
Valproate and pregnancy: think again.
Topics: Anticonvulsants; Carbamazepine; Child Development; Epilepsy; Female; Humans; Intelligence; Lamotrigi | 2015 |
[Position Statement of Hungarian Epilepsy League: The use of valproate preparations for epilepsy in pregnancy and in women of childbearing age].
Topics: Adolescent; Adult; Anticonvulsants; Cognition; Contraception; Dose-Response Relationship, Drug; Drug | 2015 |
Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations?
Topics: Adolescent; Antimanic Agents; Case-Control Studies; Child; Child, Preschool; Cleft Lip; Community He | 2008 |
Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy.
Topics: Adult; Anticonvulsants; Bias; Cleft Palate; Cohort Studies; Female; Humans; Incidence; Infant, Newbo | 2009 |
[Neonatal seizures caused by lamotrigin withdrawal?].
Topics: Adult; Anticonvulsants; Female; Humans; Infant, Newborn; Lamotrigine; Male; Maternal-Fetal Exchange; | 2009 |
Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs.
Topics: Adult; Anticonvulsants; Carbamazepine; Child, Preschool; Cognition; Developmental Disabilities; Dose | 2009 |
A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy.
Topics: Analysis of Variance; Anticonvulsants; Carbamazepine; Child, Preschool; Cognition; Creativity; Epile | 2009 |
Valproic acid: long-term effects on children exposed in utero.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Cohort Studies; Contraindications; Dose | 2009 |
Therapeutic strategies to avoid long-term adverse outcomes of neonatal antiepileptic drug exposure.
Topics: Animals; Animals, Newborn; Anticonvulsants; Corpus Striatum; Female; Humans; Lamotrigine; Mental Pro | 2010 |
Perinatal exposure to maternal lamotrigine: clinical considerations for the mother and child.
Topics: Adult; Anticonvulsants; Breast Feeding; Epilepsy; Female; Humans; Infant, Newborn; Lactation; Lamotr | 2010 |
Effects of breastfeeding in children of women taking antiepileptic drugs.
Topics: Adult; Anticonvulsants; Breast Feeding; Carbamazepine; Child, Preschool; Cognition; Epilepsy; Female | 2010 |
Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine.
Topics: Anticonvulsants; Carbamazepine; Case-Control Studies; Child, Preschool; Developmental Disabilities; | 2011 |
Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Epile | 2011 |
Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Canada; Carbamazepine; Cohort Studies; Drug Therapy, C | 2011 |
The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs.
Topics: Adult; Anticonvulsants; Carbamazepine; Case-Control Studies; Child; Child Development Disorders, Per | 2013 |
Effects of antiepileptic drugs on induced epileptiform activity in a rat model of dysplasia.
Topics: 4-Aminopyridine; Action Potentials; Animals; Animals, Newborn; Anticonvulsants; Carbamazepine; Disea | 2002 |
Valproic acid and lamotrigine treatment during pregnancy. The risk of chromosomal abnormality.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Anticonvulsants; Chromosome Aberrations | 2003 |
What can we say to women of reproductive age with epilepsy?
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; E | 2005 |
Lamotrigine and the risk of malformations in pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Europe; Female; Humans; Incidence; Infant, Newborn; La | 2005 |
Lamotrigine and the risk of malformations in pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Causality; Cross-Sectional Studies; Data Interpretatio | 2006 |
Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Cleft Palate; Epilepsy; Female; Humans; Infant; Infant | 2008 |